Misplaced Pages

Thymectacin: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 22:32, 18 September 2011 editBogBot (talk | contribs)Bots53,132 edits populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot← Previous edit Revision as of 14:55, 16 April 2013 edit undoDavidTTTaylor (talk | contribs)202 editsm WPCleaner v1.27 - Square brackets not correct end (Fixed using WP:WCW)Next edit →
Line 25: Line 25:
}} }}


'''Thymectacin''' (NB-1011, NB-101, N--2'-deoxyuridin-5'-O-yl](phenoxy)phosphoryl]-L-alanine methyl ester) is an anticancer ] of ] monophosphate. It developed by ] and it has entered in phase I clinical trials for colon cancer.<ref>{{cite journal | author= Wilson, R. H. | title = Novel Therapeutic Developments Other Than EGFR and VEGF Inhibition in Colorectal Cancer | journal = The Oncologist | volume = 11 | issue = 9 | pages = 1018–1024 | url = http://theoncologist.alphamedpress.org/cgi/content/full/11/9/1018 | doi= 10.1634/theoncologist.11-9-1018 | pmid= 17030644 | year= 2006 | last1= Wilson | first1= RH}}</ref> '''Thymectacin''' (NB-1011, NB-101, N--2'-deoxyuridin-5'-O-yl]](phenoxy)phosphoryl]-L-alanine methyl ester) is an anticancer ] of ] monophosphate. It developed by ] and it has entered in phase I clinical trials for colon cancer.<ref>{{cite journal | author= Wilson, R. H. | title = Novel Therapeutic Developments Other Than EGFR and VEGF Inhibition in Colorectal Cancer | journal = The Oncologist | volume = 11 | issue = 9 | pages = 1018–1024 | url = http://theoncologist.alphamedpress.org/cgi/content/full/11/9/1018 | doi= 10.1634/theoncologist.11-9-1018 | pmid= 17030644 | year= 2006 | last1= Wilson | first1= RH}}</ref>


==References== ==References==

Revision as of 14:55, 16 April 2013

Pharmaceutical compound
Thymectacin
Identifiers
IUPAC name
  • (2S)-methyl 2-((((2R,3S,5R)-5-(5-((E)-2-bromovinyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H25BrN3O9P
Molar mass574.3185 g/mol g·mol
  (verify)

Thymectacin (NB-1011, NB-101, N--2'-deoxyuridin-5'-O-yl]](phenoxy)phosphoryl]-L-alanine methyl ester) is an anticancer prodrug of brivudine monophosphate. It developed by New Biotics and it has entered in phase I clinical trials for colon cancer.

References

  1. Wilson, RH (2006). "Novel Therapeutic Developments Other Than EGFR and VEGF Inhibition in Colorectal Cancer". The Oncologist. 11 (9): 1018–1024. doi:10.1634/theoncologist.11-9-1018. PMID 17030644. {{cite journal}}: More than one of |author= and |last1= specified (help)


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: